DENVER --(BUSINESS WIRE)--Oct. 14, 2024-- TriSalus Life Sciences ® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod,
DENVER --(BUSINESS WIRE)--Sep. 26, 2024-- TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, has
Pressure enabled drug deliver (PEDD) method significantly increased penetration of glass microspheres into porcine liver tumors (117%; p=0.004 and 39%; p=0.032) with lobar infusions and selective infusions, respectively DENVER --(BUSINESS WIRE)--Sep. 23, 2024-- TriSalus Life Sciences®, Inc.
Reported revenues of $7.4 million in Q2 2024 and $13.8 million for six months ended June 30, 2024 , up 60% and 82%, respectively, compared to prior year periods Reported gross margin of 88% in Q2 2024 and 86% for the six months ended June 30, 2024 , compared to 83% and 81%, respectively, in the
Call Scheduled for Thursday, August 15, 2024 , at 9:00 a.m. ET DENVER --(BUSINESS WIRE)--Aug. 1, 2024-- TriSalus Life Sciences ® Inc. , (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic
WESTMINSTER, Colo. --(BUSINESS WIRE)--Jul. 1, 2024-- TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the
WESTMINSTER, Colo. --(BUSINESS WIRE)--Jun. 26, 2024-- TriSalus Life Sciences ® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today
– Hepatic arterial infusion (HAI) of nelitolimod has been well tolerated and associated with encouraging immunologic activity in patients with HCC and ICC – 4 mg dose demonstrated 3 of 3 patients achieving disease control, with one complete response in the liver (5L ICC), one partial response
DENVER --(BUSINESS WIRE)--May 24, 2024-- TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today that it has
Reported revenues of $6.5 million in 1Q24, up 116% compared to 1Q23 Reported gross margin of 85% in 1Q24 Secured up to $50 million of debt financing with OrbiMed to support TriNav® Infusion System growth initiatives Announced the appointment of Liselotte Hyveled to the Board of Directors Full year